From The Craig Bushon Show Media Team
Over the past year, the conversation around Ozempic has shifted. What started as scattered safety reports has now moved into peer-reviewed research and regulatory review.
The issue is a rare eye condition called Non-Arteritic Anterior Ischemic Optic Neuropathy — NAION — which can cause sudden, painless, and often permanent vision loss in one eye.
Here’s what the most recent data says, in clear terms.
The 2024 JAMA Ophthalmology Study
In 2024, a large matched cohort study published in JAMA Ophthalmology followed more than 16,000 patients.
Researchers found:
• In people with Type 2 diabetes, semaglutide users had about a 4-times higher risk of NAION compared to those on non-GLP-1 medications.
• Cumulative incidence over 36 months was about 8.9% vs. 1.8%.
• In patients with overweight or obesity (without diabetes), the risk appeared even higher — more than 7 times greater, with cumulative incidence around 6.7% vs. 0.8%.
Those numbers triggered serious attention in the medical community.
Important clarification: this was an observational study. That means it shows association, not guaranteed causation. Still, the magnitude of the difference raised eyebrows.
Subsequent Research: Mixed but Evolving
After that study, additional research followed.
Some larger multinational cohort studies in 2025 reported:
• No significant overall association in broader populations
• Or more modest increases — roughly 2-fold in certain diabetes groups
• Higher risk appearing mainly after longer use (2+ years)
Meta-analyses pooling multiple studies have found hazard ratios in the 2–4 range in certain contexts, particularly among patients with pre-existing vascular risk factors.
A systematic review found no broad increase in other eye diseases like diabetic retinopathy but identified NAION as the primary concern.
So the research landscape now looks like this:
There may be an increased risk.
The size of that risk varies by study.
It appears higher in certain populations.
It remains rare in absolute terms.
Regulatory Action in Europe
In 2025, the European Medicines Agency reviewed the data.
The EMA concluded NAION should be listed as a very rare side effect, potentially affecting up to 1 in 10,000 users, and recommended updating labels for:
• Ozempic
• Wegovy
• Rybelsus
The agency acknowledged some epidemiological data showing roughly a doubling of risk in certain populations.
That does not mean the drug is banned. It means the label now reflects the potential risk.
U.S. FDA Position
The U.S. Food and Drug Administration has not added NAION as a boxed warning and has not formally declared a confirmed causal relationship.
The FDA continues monitoring post-marketing data and adverse event reports.
This difference between the EMA and FDA reflects regulatory judgment, not necessarily disagreement on the existence of a signal. Agencies often move at different speeds based on how they interpret evolving data.
Understanding Absolute Risk
Even if some studies show a doubling or tripling of risk, NAION remains rare overall.
For example:
If baseline risk is 1 in 10,000
And risk doubles
That becomes 2 in 10,000
Still rare.
But if 10 million people are taking the drug, that could translate into thousands of affected individuals.
That is why the phrase “rare but meaningful at scale” matters.
Who Is Most at Risk?
NAION already occurs more often in people with:
• Diabetes
• High blood pressure
• Sleep apnea
• Smoking history
• Certain optic nerve anatomy
Many semaglutide users fall into these categories.
Some researchers also suspect rapid drops in blood sugar may contribute, especially during aggressive dose escalation.
What This Means for Patients
The benefits of semaglutide are real:
• Improved blood sugar control
• Significant weight loss
• Reduced cardiovascular events in high-risk patients
For many people with serious metabolic disease, those benefits outweigh a small potential risk.
But informed consent should include discussion of emerging data — especially for patients using the drug primarily for weight loss without major health risks.
Medical Disclaimer
This article is for educational and journalistic discussion only. It is not medical advice. The Craig Bushon Show Media Team is not a healthcare provider. Patients should consult a licensed physician before making any medication changes. Never stop prescribed medication without medical supervision. If sudden vision loss occurs, seek emergency medical care immediately.
Bottom Line
The evidence suggests a possible association between semaglutide and NAION.
Some studies show a several-fold increased risk.
Other larger studies show smaller or no significant association.
European regulators have updated labeling to reflect a very rare risk.
U.S. regulators continue monitoring but have not issued major label changes.
The absolute risk remains low.
But when millions of people use a drug, even rare risks deserve transparency.
That is not panic. That is responsible oversight.
On this show, we don’t just follow the headlines… we read between the lines to get to the bottom line of what’s really going on.
